UA80813C2 - Use of epidermal growth factor in the manufacture of a pharmaceutical injection composition for preventing diabetic limb amputation - Google Patents

Use of epidermal growth factor in the manufacture of a pharmaceutical injection composition for preventing diabetic limb amputation

Info

Publication number: UA80813C2
Authority: UA; Ukraine
Prior art keywords: growth factor; epidermal growth; manufacture; injection composition; pharmaceutical injection
Prior art date: 2001-12-20

Application number

UA20040705897A

Other languages

English (en)

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-12-20

Filing date

2002-12-04

Publication date

2007-11-12

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40239814&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA80813(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2002-12-04 Application filed filed Critical

2007-11-12 Publication of UA80813C2 publication Critical patent/UA80813C2/xx

Links

VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 title abstract 2
102000009024 Epidermal Growth Factor Human genes 0.000 title 1
101800003838 Epidermal growth factor Proteins 0.000 title 1
206010012601 diabetes mellitus Diseases 0.000 title 1
229940116977 epidermal growth factor Drugs 0.000 title 1
238000002347 injection Methods 0.000 title 1
239000007924 injection Substances 0.000 title 1
238000011542 limb amputation Methods 0.000 title 1
238000004519 manufacturing process Methods 0.000 title 1
239000000203 mixture Substances 0.000 title 1
208000008960 Diabetic foot Diseases 0.000 abstract 1
238000002266 amputation Methods 0.000 abstract 1
230000001684 chronic effect Effects 0.000 abstract 1
230000008595 infiltration Effects 0.000 abstract 1
238000001764 infiltration Methods 0.000 abstract 1
230000007654 ischemic lesion Effects 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1808—Epidermal growth factor [EGF] urogastrone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/465—Nicotine; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Gastroenterology & Hepatology (AREA)
Chemical Kinetics & Catalysis (AREA)
Dermatology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Zoology (AREA)
Diabetes (AREA)
Molecular Biology (AREA)
Hematology (AREA)
Biomedical Technology (AREA)
Emergency Medicine (AREA)
Urology & Nephrology (AREA)
Endocrinology (AREA)
Cardiology (AREA)
Obesity (AREA)
Vascular Medicine (AREA)
Pain & Pain Management (AREA)
Heart & Thoracic Surgery (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

UA20040705897A 2001-12-20 2002-12-04 Use of epidermal growth factor in the manufacture of a pharmaceutical injection composition for preventing diabetic limb amputation UA80813C2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
CU20010308A CU23043A1 (es)	2001-12-20	2001-12-20	Composicion farmaceutica que contiene factor de crecimiento epidrmico (egf) para la prevencion de la amputacion de pie diabetico.
PCT/CU2002/000011 WO2003053458A1 (es)	2001-12-20	2002-12-04	Uso de una composición farmacéutica que contiene factor de crecimiento epidérmico (egf) para la prevención de la amputación del pie diabético

Publications (1)

Publication Number	Publication Date
UA80813C2 true UA80813C2 (en)	2007-11-12

Family

ID=40239814

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UA20040705897A UA80813C2 (en)	2001-12-20	2002-12-04	Use of epidermal growth factor in the manufacture of a pharmaceutical injection composition for preventing diabetic limb amputation

Country Status (21)

Country	Link
US (2)	US7465704B2 (es)
EP (1)	EP1466617B1 (es)
JP (1)	JP4808378B2 (es)
KR (1)	KR100795654B1 (es)
CN (1)	CN1306954C (es)
AR (1)	AR037824A1 (es)
AT (1)	ATE422897T1 (es)
AU (1)	AU2002361923B2 (es)
BR (1)	BRPI0215214B8 (es)
CA (1)	CA2470971C (es)
CU (1)	CU23043A1 (es)
DE (1)	DE60231248D1 (es)
DK (1)	DK1466617T3 (es)
ES (1)	ES2322568T3 (es)
MX (1)	MXPA04005831A (es)
MY (1)	MY139214A (es)
PT (1)	PT1466617E (es)
RU (1)	RU2289424C2 (es)
SI (1)	SI1466617T1 (es)
UA (1)	UA80813C2 (es)
WO (1)	WO2003053458A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CU23043A1 (es)	2001-12-20	2005-05-20	Ct Ingenieria Genetica Biotech	Composicion farmaceutica que contiene factor de crecimiento epidrmico (egf) para la prevencion de la amputacion de pie diabetico.
CU23529A1 (es) *	2005-03-02	2010-06-17	Ct Ingenieria Genetica Biotech	Combinación de egf/ghrp-6 para la neuroregeneración del sistema nervioso central posterior al dano autoinmune
CU23411B6 (es) *	2005-12-29	2009-09-08	Ct Ingenieria Genetica Biotech	Uso tópico del factor de crecimiento epidérmico en liposomas para prevenir la amputación del pie diabético
CU23388B6 (es) *	2006-01-31	2009-07-16	Ct Ingenieria Genetica Biotech	Composición farmacéutica de microesferas para prevenir la amputación del pie diabético
CU23558A1 (es)	2006-02-28	2010-07-20	Ct Ingenieria Genetica Biotech	Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento
CU23526B6 (es)	2006-10-03	2010-05-19	Ct Ingenieria Genetica Biotech	Método para la restauración morfofuncional de nervios periféricos en la neuropatía diabética
US8211947B2 (en) *	2008-01-28	2012-07-03	Guillermo Selman-Housein Sosa	Composition and method for treating and preventing musculoskeletal and connective tissue disorders
ES2340902B1 (es)	2008-07-01	2011-05-03	Laboratorios Farmaceuticos Rovi, S.A.	Composicion farmaceutica con glicosaminoglicanos y su uso en tratamiento de ulceras cronicas.
CN101496486B (zh) *	2009-03-13	2011-02-16	新疆巴音郭楞蒙古自治州农业科学研究所	一种蘑菇栽培方法
ES2357601B1 (es)	2011-01-26	2012-03-21	Laboratorios Farmacéuticos Rovi, S.A.	Procedimiento de preparación de derivados de glicosaminoglicanos donadores de óxido n�?trico y su uso en tratamiento de úlceras crónicas.
ES2468740B1 (es)	2012-11-13	2015-04-01	Consejo Superior De Investigaciones Científicas (Csic)	Apósito para cicatrización de heridas comprometidas
US9579257B2 (en)	2013-08-20	2017-02-28	Anutra Medical, Inc.	Haptic feedback and audible output syringe
USD774182S1 (en)	2014-06-06	2016-12-13	Anutra Medical, Inc.	Anesthetic delivery device
USD750768S1 (en)	2014-06-06	2016-03-01	Anutra Medical, Inc.	Fluid administration syringe
USD763433S1 (en)	2014-06-06	2016-08-09	Anutra Medical, Inc.	Delivery system cassette
CN104173366A (zh) *	2014-09-14	2014-12-03	陈钏黄	一种三磷酸腺苷二钠在制备治疗糖尿病足药物中的应用
MX389934B (es) *	2016-12-09	2025-03-20	Desarrolladora Y Com De Tecnologias Biomedicas Decotecbio S A De C V	Composición coadyuvante de un factor de crecimiento y un neuropéptido para acelerar la cicatrización de heridas y la repitelización de órganos.
US20210155896A1 (en) *	2017-06-28	2021-05-27	Rutgers, The State University Of New Jersey	Single brain cell-derived organoids
WO2019006127A1 (en) *	2017-06-28	2019-01-03	Rutgers, The State University Of New Jersey	ORGANOIDS DERIVED FROM A SINGLE RENAL CELL
CU20190022A7 (es) *	2019-03-18	2020-10-20	Centro De Ingenieria Genetica Y Biotecnologia Biocubafarma	Composición farmacéutica para el tratamiento de la úlcera del pie diabético
KR102581240B1 (ko)	2020-09-21	2023-09-22	고려대학교 산학협력단	유전자의 특이적 메틸화를 이용하여 당뇨족부궤양 재발 또는 예후를 예측하는 방법
WO2022060178A1 (ko)	2020-09-21	2022-03-24	고려대학교 산학협력단	유전자의 특이적 메틸화를 이용하여 당뇨족부궤양 재발 또는 예후를 예측하는 방법
KR102838081B1 (ko)	2022-04-12	2025-07-24	고려대학교 산학협력단	마이크로바이옴을 이용하여 당뇨족부궤양 예후를 예측하는 방법
WO2025242247A1 (es)	2024-05-21	2025-11-27	Centro De Ingeniería Genética Y Biotecnología	Uso del péptido ghrp-6 para el tratamiento de la senescencia y la cicatrización de heridas crónicas complejas refractarias

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1417776A (en) *	1973-03-28	1975-12-17	Ici Ltd	Pharmaceutical compositions
IE52535B1 (en)	1981-02-16	1987-12-09	Ici Plc	Continuous release pharmaceutical compositions
NZ226171A (en)	1987-09-18	1990-06-26	Ethicon Inc	Gel formulation containing polypeptide growth factor
JP2670680B2 (ja)	1988-02-24	1997-10-29	株式会社ビーエムジー	生理活性物質含有ポリ乳酸系微小球およびその製造法
US5034375A (en)	1988-08-10	1991-07-23	Institute Of Molecular Biology, Inc.	Process of wound healing using PDGF and EGF
US4944948A (en)	1989-02-24	1990-07-31	Liposome Technology, Inc.	EGF/Liposome gel composition and method
WO1990011781A1 (en)	1989-04-04	1990-10-18	Alcon Laboratories, Inc.	The use of liposomes for the delivery of therapeutic agents to wounds, cuts and abrasions
US5130298A (en) *	1989-05-16	1992-07-14	Ethicon, Inc.	Stabilized compositions containing epidermal growth factor
WO1991001719A1 (en)	1989-08-01	1991-02-21	The University Of Michigan	Topical delivery of peptides/proteins entrapped in dehydration/rehydration liposomes
AU629316B2 (en)	1990-04-11	1992-10-01	Flora Inc.	Periodontal disease treatment system
ATE212554T1 (de) *	1990-11-27	2002-02-15	American Nat Red Cross	Gewebeabdeckung und wachstumsfaktor enthaltende verbindungen zur förderung beschleunigter wundheilung
CN1160582A (zh) *	1996-12-27	1997-10-01	暨南大学生物工程研究所	含有细胞生长因子的皮肤外用组合物
RU2144831C1 (ru) *	1998-11-02	2000-01-27	Дальневосточный государственный медицинский университет	Способ лечения синдрома диабетической стопы
DE60139874D1 (de) *	2000-07-28	2009-10-22	Christopher J Murphy	Medium für transplantat
CU23043A1 (es)	2001-12-20	2005-05-20	Ct Ingenieria Genetica Biotech	Composicion farmaceutica que contiene factor de crecimiento epidrmico (egf) para la prevencion de la amputacion de pie diabetico.
AU2003213985A1 (en)	2002-03-12	2003-09-22	Bio-Click Technologies Ltd.	Method and composition for treating skin wounds with epidermal growth factor
CN1720989A (zh)	2004-07-15	2006-01-18	深圳市清华源兴生物医药科技有限公司	一种表皮生长因子缓释微球及其制备方法与应用

2001
- 2001-12-20 CU CU20010308A patent/CU23043A1/es unknown
2002
- 2002-12-04 CN CNB02828268XA patent/CN1306954C/zh not_active Expired - Lifetime
- 2002-12-04 DK DK02796491T patent/DK1466617T3/da active
- 2002-12-04 WO PCT/CU2002/000011 patent/WO2003053458A1/es not_active Ceased
- 2002-12-04 EP EP02796491A patent/EP1466617B1/en not_active Expired - Lifetime
- 2002-12-04 AU AU2002361923A patent/AU2002361923B2/en not_active Expired
- 2002-12-04 PT PT27964915T patent/PT1466617E/pt unknown
- 2002-12-04 RU RU2004122091/15A patent/RU2289424C2/ru active
- 2002-12-04 SI SI200230818T patent/SI1466617T1/sl unknown
- 2002-12-04 JP JP2003554215A patent/JP4808378B2/ja not_active Expired - Fee Related
- 2002-12-04 DE DE60231248T patent/DE60231248D1/de not_active Expired - Lifetime
- 2002-12-04 BR BRPI0215214A patent/BRPI0215214B8/pt not_active IP Right Cessation
- 2002-12-04 ES ES02796491T patent/ES2322568T3/es not_active Expired - Lifetime
- 2002-12-04 KR KR1020047009772A patent/KR100795654B1/ko not_active Expired - Lifetime
- 2002-12-04 MX MXPA04005831A patent/MXPA04005831A/es active IP Right Grant
- 2002-12-04 US US10/499,457 patent/US7465704B2/en not_active Expired - Lifetime
- 2002-12-04 UA UA20040705897A patent/UA80813C2/xx unknown
- 2002-12-04 CA CA2470971A patent/CA2470971C/en not_active Expired - Lifetime
- 2002-12-04 AT AT02796491T patent/ATE422897T1/de active
- 2002-12-13 AR ARP020104843A patent/AR037824A1/es active IP Right Grant
- 2002-12-18 MY MYPI20024760A patent/MY139214A/en unknown
2008
- 2008-08-22 US US12/197,001 patent/US7799760B2/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
AR037824A1 (es)	2004-12-09
KR100795654B1 (ko)	2008-01-21
US7465704B2 (en)	2008-12-16
JP2005516024A (ja)	2005-06-02
BRPI0215214B8 (pt)	2021-05-25
WO2003053458A1 (es)	2003-07-03
ES2322568T3 (es)	2009-06-23
US20080312139A1 (en)	2008-12-18
RU2289424C2 (ru)	2006-12-20
SI1466617T1 (sl)	2009-08-31
MXPA04005831A (es)	2004-09-13
US20050107294A1 (en)	2005-05-19
MY139214A (en)	2009-08-28
CA2470971A1 (en)	2003-07-03
CN1620308A (zh)	2005-05-25
KR20040094669A (ko)	2004-11-10
CA2470971C (en)	2011-02-01
DK1466617T3 (da)	2009-06-15
CN1306954C (zh)	2007-03-28
BRPI0215214B1 (pt)	2017-05-30
HK1077740A1 (en)	2006-02-24
CU23043A1 (es)	2005-05-20
JP4808378B2 (ja)	2011-11-02
US7799760B2 (en)	2010-09-21
EP1466617B1 (en)	2009-02-18
PT1466617E (pt)	2009-05-20
AU2002361923B2 (en)	2006-02-02
AU2002361923A1 (en)	2003-07-09
RU2004122091A (ru)	2005-04-10
DE60231248D1 (de)	2009-04-02
BR0215214A (pt)	2004-12-07
ATE422897T1 (de)	2009-03-15
EP1466617A1 (en)	2004-10-13

Publication	Publication Date	Title
UA80813C2 (en)	2007-11-12	Use of epidermal growth factor in the manufacture of a pharmaceutical injection composition for preventing diabetic limb amputation
MY143742A (en)	2011-07-15	Pharmaceutical composition of microspheres for preventing diabetic limb amputation
GB0001309D0 (en)	2000-03-08	Valve arrangement
WO2006117459A3 (fr)	2006-12-28	Orthese compressive de contention du membre inférieur en forme d'article tricoté de type bas, chaussette ou collant
ES2162393T3 (es)	2001-12-16	Terapia de combinacion para erradicar el hcv-rna detectable en pacientes con infeccion de hepatitis c cronica.
WO2003032815A3 (en)	2003-11-06	Medical device for delivering patches
IL149176A0 (en)	2002-11-10	Therapeutic use
MXPA04006395A (es)	2004-10-04	Una formulacion farmaceutica liquida que comprende nicotina para la administracion en la cavidad oral.
CY1112753T1 (el)	2016-02-10	Θεραπευτικη αγωγη καρκινων του ανθρωπινου σωματος με τη χρηση toy ετ743
WO2003073981A3 (en)	2003-11-27	Novel of cytokine inhibitors
BR0316523A (pt)	2005-10-18	Composto, composição farmacêutica e método para tratar ou prevenir câncer em um paciente
DE602006016799D1 (de)	2010-10-21	NEUE, HYALURONSÄURE ODER HYALURONSàURE DERIVATE UND COLLAGENASE ENTHALTENDE PHARMAZEUTISCHE ZUSAMMENSETZUNGEN ZUR TOPISCHEN BEHANDLUNG VON WUNDEN, VERBRENNUNGEN UND GESCHWÜREN
EP1338270A3 (fr)	2005-10-05	Utilisation dans un traitement cosmétique d'une fraction phénolique riche en dihydrochalcones
SI1799186T1 (sl)	2008-10-31	Pastile, ki vsebujejo oktenidin, proti vnetnim boleznim ust in Ĺľrela
GB0020504D0 (en)	2000-10-11	Therapeutic method
WO2001070255A3 (en)	2002-02-28	Combined treatment with keratinocyte growth factor and epidermal growth factor inhibitor
MY184122A (en)	2021-03-19	Use of topical composition containing epidermal growth factor (egf) for diabetic foot amputation prevention
MXPA02006511A (es)	2004-08-11	Complejo que comprende factor inhibidor de osteoclastogenesis y polisacarido.
MX2008001520A (es)	2008-04-07	Composiciones de tizanidina y metodos de tratamiento usando las composiciones.
NZ519722A (en)	2004-12-24	Treatment of diabetic ulcers
EP1051976A3 (en)	2002-10-23	Use of bisphosphate for the treatment of osteogenesis imperfecta
BR0213823A (pt)	2004-08-31	Método de administração de um peptìdeo timosina alfa 1
DE60120917D1 (de)	2006-08-03	Kombinationspräparat zur krebstherapie
EA201000501A1 (ru)	2010-10-29	Фармацевтическая композиция, содержащая не обладающий нейротоксичностью активатор плазминоген для лечения удара
SE0200598D0 (sv)	2002-02-27	Pharmaceutical composition and method for treatment or prevention of vascular disease or states of tissue hypoperfusion with hypoxic and/or ischemic consequences